Updated Integrated Safety Analysis of Ritlecitinib Up to Five Years in Adolescents With Alopecia Areata From the ALLEGRO Clinical Trials

    November 2025 in “ SKIN The Journal of Cutaneous Medicine ”
    Lidia Rudnicka, J. Mazereeuw‐Hautier, Ilka Arun Netravali … Helen Tran
    Studysummary This study evaluated the long-term safety of ritlecitinib in adolescents with alopecia areata and found it to be well-tolerated without new safety concerns over approximately five years, with common adverse events including positive SARS-CoV-2 tests, acne, headache, and nasopharyngitis.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on skin.dermsquared.com →
    Discuss this study in the Community →

    Research cited in this study 3

    1. Efficacy and Safety of Ritlecitinib in Adolescents with Alopecia Areata: Results from the ALLEGRO Phase 2b/3 Randomized, Double-Blind, Placebo-Controlled Trial Pediatric Dermatology · 2023
    2. Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial The Lancet · 2023
    3. The Autoimmune Basis of Alopecia Areata: A Comprehensive Review Autoimmunity reviews · 2014